BRAIN Act

HR 2767, the BRAIN Act, aims to advance brain tumor research and improve patient care by requiring the NIH to create a public database of tumor samples collected with federal funding. It authorizes $50 million annually for a Glioblastoma Therapeutics Network to accelerate treatment development and $10 million for cellular immunotherapy research (including CAR-T therapies) targeting brain tumors. The bill also mandates a national awareness campaign to increase understanding of cancer clinical trials and biomarker testing, plus $5 million yearly for pilot programs studying survivor care coordination and follow-up services. Additionally, it directs the FDA to issue guidance ensuring brain tumor patients can access clinical trials. These provisions directly affect patients, researchers, and healthcare providers focused on brain tumors and rare cancers.